Zedcor Logo
CA98923V1094
A3D768
ZDC.V

Zedcor

Loading quotes...

Forecast

Buy
  1
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2016, Zedcor has already paid €0.0126 in dividends. The last payout was in January 2016.

Financials

In the last year, Zedcor had revenue of €16.99m and net profit of €1.81m
(EUR) 2023
YoY
Revenue 16.99m 11.92%
Gross profit 8.46m 14.25%
Net profit 1.81m 56.06%
EBITDA 4.84m 15.97%

Fundamentals

Metric Value
Market capitalization
€203.27m
Number of shares
96.05m
52-week high/low
€2.35 - €0.35
Dividends No
Beta
2.47
P/E ratio
-124.30
PEG ratio
-2.62
P/B ratio
5.63
P/S ratio
6.32

Company profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Name
Zedcor
CEO
Todd Michael Ziniuk
Headquarters Calgary, ab
USA
Website
Sector
Energy
Industry
Oil, Gas & Consumable Fuels
IPO
04/02/2015
Employees 100

Ticker symbols

Exchange Symbol
Tsxv
ZDC.V
Pnk
CRFQF
🍪

Parqet  uses cookies. Learn more